Health Information Search Results
Peer Reviewed Scientific Research Reports.
|<< Prev 20 ||Showing 1 to 4 of 4 Matches||Next 20 >>|
1. Anti-GT1a IgG antibodies in a child with severe Guillain-Barre syndrome.
Match Strength: 19.450
This report describes a male, age 8 years 10 months, with severe Guillain-Barre syndrome after Campylobacter jejuni infection. The patient developed fulminant muscle weakness, external ophthalmoplegia, bulbar palsy, and respiratory distress. A high level of serum monospecific anti-GT1a immunoglobulin G antibody was detected. He was treated with intravenous immunoglobulins and artificial ventilation. Two years after the onset, the patient still suffered from residual leg weakness and foot drop. After 3 years and clinical recovery, the antibody was no longer detectable. This report presents the ... Read More »
» Published in Pediatr Neurol. 2006 Oct;35(4):277-9.
2. Residual fatigue is independent of antecedent events and disease severity in Guillain-Barre syndrome.
Match Strength: 17.432
The occurrence of severe fatigue after Guillain-Barre syndrome (GBS), and its relation with disease course, clinical characteristics, and antecedent infections was studied in 100 GBS patients. Severe fatigue, expressed as a mean Fatigue Severity Scale (FSS) score of 5.0 or more, was present in 60% of all patients. It was more frequently present in females and in patients over 50 years (p < 0.01). There was no significant relationship between fatigue severity and the level of functional disability at nadir, antecedent events or infections, clinical variables, and time to follow-up after GBS ... Read More »
» Published in J Neurol. 2006 Sep;253(9):1143-6. Epub 2006 Sep 22.
3. Epidemiology of neuroimmunological diseases.
Match Strength: 12.486
This review gives an overview of various neuroimmunological diseases in terms of incidence and prevalence rates, age and sex distribution, and the frequency of subtypes, if applicable. The disorders selected for review are inflammatory muscle disorders (polymyositis, dermatomyositis and inclusion body myositis), myasthenia gravis, immune-mediated polyneuropathies (Guillain-Barre syndrome, chronic polyneuritis and vasculitic neuropathies), and multiple sclerosis ... Read More »
» Published in J Neurol. 2006 Sep;253(Supplement 5):v2-v8.
4. Basic principles of intravenous immunoglobulin (IVIg) treatment.
Match Strength: 9.885
The original rationale for the therapeutic application of immunoglobulins was prevention and treatment of infectious diseases. With the description of agammaglobulinemia, substitution therapy became the primary indication for the use of immunoglobulins. Limitations and side effects of the intramuscular administration of immunoglobulins led to the development of preparations for intravenous use (IVIg). In the early 1980s an immunomodulatory effect of IVIg was described. Since then, the efficacy of IVIg has been established in controlled trials for diseases like idiopathic thrombocytopenic ... Read More »
» Published in J Neurol. 2006 Sep;253 Suppl 5:v18-v24.
|<< Prev 20 ||Showing results 1 to 4 of 4||Next 20 >>|
* All information on Level1Diet.com is for educational purposes only. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease. Before changing your diet, or adding supplements to your diet, or beginning an exercise program, everyone should consult a qualified and licensed health practitioner; a physician, dietician or similar professional.